Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Oryzon Genomics (BME: ORY) further strengthens vafidemstat’s intellectual property profile >

Arron Aatkar, PhD | Healthcare | Comment | 15 hours ago

Oryzon Genomics (BME: ORY) further strengthens vafidemstat’s intellectual property profile >

Arron Aatkar, PhD | Healthcare | Comment | 15 hours ago

SEE ALL COMMENTARY >

Medigene (MDG1)

Latest price

EUR0.13

▾ −0.05 (−27.57)

As at 11/07/2025

Market capitalisation: EUR2m

Equities

Equities by Sector

Sectors

Thematics

Latest

Results from Edison’s Investor Survey

Decarbonising the built environment – Green materials, greener buildings

The advertising ecosystem – Triangulating perspectives

Audiovisual

Latest

Team Internet – executive interview

Halyk Bank in 60 seconds

bp — capital markets update (part 2)

About Edison

About Edison

Careers

Healthcare Equities

Medigene (MDG1)

EUR0.13

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Medigene – executive interview

See morecontent on

Mendus (IMMU)

SEK7.34

Mendus — Another encouraging ovarian cancer update

Mendus – executive interview

Mendus — No surprises in Q125 update

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF7.17

Newron Pharmaceuticals — Evenamide enters ENIGMA-TRS programme

Newron Pharmaceuticals – executive interview

Newron Pharmaceuticals — Next stage unlocked for evenamide

See morecontent on

Nykode Therapeutics (NYKD)

NOK1.74

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Ocugen (OCGN)

—

Okyo Pharma (OKYO)

USD2.81

Okyo Pharma — Targeting underserved corneal diseases

See morecontent on

Oncopeptides (ONCO)

SEK3.65

OpGen (OPGN)

—

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR2.85

Oryzon Genomics — KOL event highlights vafidemstat potential in BPD

Oryzon Genomics — A step closer to a new treatment paradigm in BPD

Oryzon Genomics — Preparations in place for an active 2025

See morecontent on

OSE Immunotherapeutics (OSE)

EUR5.07

OSE Immunotherapeutics — New UC biomarker underpins growth strategy

OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential

OSE Immunotherapeutics — Strategic collaboration in mRNA technologies

See morecontent on

Percheron Therapeutics (PER)

AUD0.01

Recce Pharmaceuticals (RCE)

AUD0.33

Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials

Recce Pharmaceuticals — Gearing up for an eventful year for R327G

Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results

See morecontent on

Saniona (SANION)

SEK9.69

Saniona — Broad pipeline to address neurological conditions

See morecontent on

Santhera Pharmaceuticals (SANN)

CHF12.20

Sareum Holdings (SAR)

GBP0.18

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on